Compare Edgewise Therapeutics Inc. Common Stock (EWTX) vs Sibanye Stillwater Ltd (SBSW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Edgewise Therapeutics Inc. Common Stock vs Sibanye Stillwater Ltd — how do they compare? Edgewise Therapeutics Inc. Common Stock trades at $38.1 (market cap $4.02B), while Sibanye Stillwater Ltd trades at $9.55 (market cap $6.73B). The key difference: Sibanye Stillwater Ltd is the larger of the two by market cap, and Sibanye Stillwater Ltd pays a 8.59% dividend while Edgewise Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Edgewise Therapeutics Inc. Common Stock for 0 Days and Sibanye Stillwater Ltd for 51 Days on average.
| EWTX | SBSW | |
|---|---|---|
Market Cap | $4.02B | $6.73B |
Volume | 1,446,128 | 4,495,821 |
Sector | Health | Basic Materials |
52-Week High | $48.35 | $21.12 |
52-Week Low | $14.89 | $8.00 |
Typical Hold Time | 0 Days | 51 Days |
Enterprise Value | $3.56B | $7.64B |
Dividend Yield | — | 8.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Sibanye Stillwater (SBSW) trades at $9.91, up 0.2% with bearish technical signals despite strong Q2 2026 earnings beat. The company shows improving fundamentals with revenue growth to $129.68B in 2025 and projected $164.9B in 2026, though net losses persist. Analyst consensus is moderately bullish with a $14.25 price target, representing 44% upside potential from current levels.
The stock presents a value opportunity with attractive valuation ratios (P/E 7.72, P/S 0.67) and strong profitability metrics (ROE 34.37%). Key risks include volatile commodity prices and persistent net losses despite revenue growth. Institutional ownership trends show confidence with MAC Alpha Capital increasing holdings by 81.4% in Q2 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Edgewise Therapeutics Inc. Common Stock
Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops small-molecule therapies based on its research in muscle physiology, with a pipeline focused on cardiovascular and cardiometabolic conditions such as hypertrophic cardiomyopathy and heart failure.
Read more on EWTX →About Sibanye Stillwater Ltd
Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →
